RT Journal Article
SR Electronic
T1 Clinical Utility of Transarterial Infusion Chemotherapy Using Cisplatin-lipiodol Emulsion for Unresectable Hepatocellular Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4923
OP 4930
VO 32
IS 11
A1 TETSUYA BEPPU
A1 KAZUSHI SUGIMOTO
A1 KATSUYA SHIRAKI
A1 MASAHIKO TAMEDA
A1 YUJI INAGAKI
A1 SUGURU OGURA
A1 CHIKA KASAI
A1 SATOKO KUSAGAWA
A1 KEIICHIRO NOJIRI
A1 MISAO YONEDA
A1 HIROYUKI FUKE
A1 NORIHIKO YAMAMOTO
A1 YOSHIYUKI TAKEI
A1 MASASHI FUJIMORI
A1 TAKAAKI HASEGAWA
A1 TAKASHI YAMANAKA
A1 JUNICHI URAKI
A1 MASATAKA KASHIMA
A1 HARUYUKI TAKAKI
A1 ATSUHIRO NAKATSUKA
A1 KOICHIRO YAMAKADO
A1 KAN TAKEDA
YR 2012
UL http://ar.iiarjournals.org/content/32/11/4923.abstract
AB Background: We evaluated the clinical efficacy of transarterial infusion chemotherapy using a cisplatin-lipiodol emulsion for unresectable hepatocellular carcinoma (HCC). Patients and Methods: Fifty-seven patients with advanced HCC, with no indications for surgical resection or local ablative therapy, such as percutaneous ethanol injection and radiofrequency ablation, were enrolled in this retrospective study. Results: Twelve patients were treated with cisplatin-alone at a dose of 65 mg/m2 by infusion into the artery. Forty-two patients were treated with the same dose of cisplatin suspended in 1-10 ml of lipiodol (C/LPD). Cumulative survival rates in the cisplatin-treated group were 46.2% at one year, and 18.5% at two years, whereas these in the C/LPD group were 81.6% and 44.4%, respectively, with a significant difference between the two groups (p<0.01). In the cisplatin-treated group (n=13), no (0%) patients had a complete response (CR), two (15%) a partial response (PR), three (23%) no change (NC), and eight (62%) progressive disease (PD). In the C/LPD group (n=44), four (9%) patients had CR, 16 (35%) PR, 12 (26%) NC, and 12 (26%) PD. CR and PR were seen in 15% of the cisplatin-treated group and in 44% of the C/LPD group. C/LPD was significantly more effective than cisplatin-alone (p=0.039). Some patients showed tumor response to C/LPD after intra-arterial infusion of low-dose 5-fluorouracil. Conclusion: C/LPD produced superior effects compared to cisplatin-alone for unresectable HCC, causing no major side-effects, and increasing the survival rate.